JT003 is a synthetic adiponectin agonist against receptors AdipoR1 and AdipoR2 and has proved effective in reducing the activation of hepatic stellate cells in non-alcoholic steatohepatitis (NASH) and liver fibrosis. Here, ADIPOQ is linked to metabolic dysfunction-associated steatohepatitis.